Cuban regulation authority authorizes registration of drug for the treatment of Alzheimer´s Disease

The regulatory body said on Tuesday that conditional registration is established to confirm the results of the Phase 3 clinical efficacy study.

The registration granted will be valid for three years from the date of issuance of the registration certificate.

Neuro-Epo, developed by the Molecular Engineering  Center in collaboration with other BioCubaFarma institutions,  is a nasal formulation.

The results of the Phase II-III clinical trial with this product in patients with mild and moderate Alzheimer’s disease were encouraging, as recently reported by CIM authorities.